Travere Therapeutics (TVTX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for May 19, 2026, with voting on five key proposals, including director elections, equity plan amendment, executive compensation, advisory vote frequency, and auditor ratification.

• Proxy materials are provided electronically to reduce costs and environmental impact; shareholders can vote online, by phone, mail, or in person.

• Only shareholders of record as of March 23, 2026, are eligible to vote; 92,369,812 shares outstanding.

• Forward-looking statements address clinical programs, regulatory filings, and commercial launches, with risks detailed in the annual report.

Voting matters and shareholder proposals

• Election of ten directors for one-year terms.

• Approval to amend the 2018 Equity Incentive Plan, increasing authorized shares by 3,000,000.

• Advisory vote on executive compensation (say-on-pay) and on the frequency of such votes (recommended: annually).

• Ratification of Ernst & Young LLP as independent auditor for fiscal 2026.

• Shareholder proposals for the 2027 meeting must be submitted by December 7, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• Board consists of ten directors, nine of whom are independent; CEO is the only non-independent member.

• Board leadership structure separates CEO and Chair roles to enhance oversight and accountability.

• Committees include Audit, Compensation, Nominating/Corporate Governance, and Science & Medical Technology, all with independent members.

• Annual board and committee self-assessments are conducted for effectiveness.

• Stock ownership guidelines are in place for directors and executives.